Establishment of a New Cell Line of Canine Mammary Tumor CMT-1026

Overview

Journal Front Vet Sci

Specialty Veterinary Medicine

Date 2021 Oct 29

PMID 34712723

Citations 3

Authors

Chen Mei

Liang Xin

Yang Liu

Jiabao Lin

Hong Xian

Xue Zhang

Wei Hu

Zhaofei Xia

Hongjun Wang

Yanli Lyu

Affiliations

Soon will be listed here.

Abstract

Canine mammary tumors (CMTs) have histopathological, epidemiologic and clinical characteristics similar to those in humans and are known to be one of the best models for human breast cancer (HBC). This research aimed to describe a newly established canine cell line, CMT-1026. Tumor samples were collected from a female dog exhibiting clinical mammary neoplasm, and the adherent cells were cultured. Both the histology and immunohistochemistry (IHC) of tumor samples were estimated. Cell growth, ultrastructural, cytological and immunocytochemistry (ICC) features of CMT-1026 were examined. CMT-1026 cells were inoculated into 10 female BALB/c nude mice to evaluate oncogenicity and metastatic ability. Hematoxylin-eosin (H.E.) staining of the tumors revealed an epithelial morphology. Electron microscopy was used to detect histological and cytological of smears, and ultrathin sections showed that CMT-1026 cells were polygonal and characterized by atypia and high mitotic index in the tumor, with prominent nucleoli and multinucleated cells. IHC characterization of CMT-1026 indicated ER-, PR-, HER-2, p63+, CK5/6+, and α-SMA+ epithelial cells. ICC characterization of CMT-1026 showed high expression of Claudin-1, Delta-catenin, SOX-2, and KI-67. At 2 weeks after inoculation of the CMT-1026 cells, phyma was found in 100% of the mice. The xenograft cancers showed conservation of the original H.E. features of the female dog cancer. In conclusion, CMT-1026 may be a model of canine mammary cancer that can be used in research on the pathogenesis of both CMT and HBC.

Citing Articles

Anticancer Effects of Mitoquinone via Cell Cycle Arrest and Apoptosis in Canine Mammary Gland Tumor Cells.

Lee R, Lee W, Park H Int J Mol Sci. 2024; 25(9).

PMID: 38732133 PMC: 11084895. DOI: 10.3390/ijms25094923.

Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines.

Yeom J, Cho Y, Ahn S, Jeung S Front Vet Sci. 2023; 10:1279535.

PMID: 38033642 PMC: 10684731. DOI: 10.3389/fvets.2023.1279535.

A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer.

Inglebert M, Dettwiler M, Hahn K, Letko A, Drogemuller C, Doench J Sci Rep. 2022; 12(1):18051.

PMID: 36302863 PMC: 9614008. DOI: 10.1038/s41598-022-21706-2.

References

Reddy S, Carroll E, Nanda R . Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020; 20(3):151-158. DOI: 10.1080/14737140.2020.1732211. View

Rody A, Loibl S, Kaufmann M . [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006]. Zentralbl Gynakol. 2006; 128(5):233-41. DOI: 10.1055/s-2006-942205. View

Boyle S, Mittal P, Kaur G, Hoffmann P, Samuel M, Klingler-Hoffmann M . Uncovering Tumor-Stroma Inter-relationships Using MALDI Mass Spectrometry Imaging. J Proteome Res. 2020; 19(10):4093-4103. DOI: 10.1021/acs.jproteome.0c00511. View

Custodio P, Colombo J, Ventura F, Castro T, Zuccari D . Melatonin Treatment Combined with TGF-β Silencing Inhibits Epithelial- Mesenchymal Transition in CF41 Canine Mammary Cancer Cell Line. Anticancer Agents Med Chem. 2020; 20(8):989-997. DOI: 10.2174/1871520620666200407122635. View

Bonacho T, Rodrigues F, Liberal J . Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem. 2019; 95(2):71-91. DOI: 10.1080/10520295.2019.1651901. View

Dos Reis D, Damasceno K, de Campos C, Veloso E, Pegas G, Kraemer L . Versican and Tumor-Associated Macrophages Promotes Tumor Progression and Metastasis in Canine and Murine Models of Breast Carcinoma. Front Oncol. 2019; 9:577. PMC: 6616078. DOI: 10.3389/fonc.2019.00577. View

Hammer S, Nagel S, Junginger J, Hewicker-Trautwein M, Wagner S, Heisterkamp A . Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate carcinoma and mammary tissue derived cell lines. Neoplasma. 2016; 63(2):231-8. DOI: 10.4149/208_150924N505. View

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho J . FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019; 30(8):1289-1297. DOI: 10.1093/annonc/mdz177. View

10.

Emens L . Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2017; 24(3):511-520. PMC: 5796849. DOI: 10.1158/1078-0432.CCR-16-3001. View

11.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

12.

Beauvais W, Cardwell J, Brodbelt D . The effect of neutering on the risk of mammary tumours in dogs--a systematic review. J Small Anim Pract. 2012; 53(6):314-22. DOI: 10.1111/j.1748-5827.2011.01220.x. View

13.

Rasotto R, Berlato D, Goldschmidt M, Zappulli V . Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases. Vet Pathol. 2017; 54(4):571-578. DOI: 10.1177/0300985817698208. View

14.

Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976-83. DOI: 10.1200/JCO.2003.02.063. View

15.

Caceres S, Pena L, de Andres P, Illera M, Lopez M, Woodward W . Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366. PLoS One. 2015; 10(3):e0122277. PMC: 4373858. DOI: 10.1371/journal.pone.0122277. View

16.

Skalova H, Hajkova N, Majerova B, Bartu M, Povysil C, Ticha I . Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer. Exp Ther Med. 2019; 18(4):3014-3024. PMC: 6755479. DOI: 10.3892/etm.2019.7930. View

17.

Hildenbrand R, Schaaf A . The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol. 2008; 34(1):15-23. View

18.

da Rocha A, Carvalheira J, Gartner F . α-catenin, β-catenin and P-120-catenin immunoexpression in canine mammary tissues and their relationship with E-cadherin. Res Vet Sci. 2020; 130:197-202. DOI: 10.1016/j.rvsc.2020.03.002. View

19.

Ullah M . Breast Cancer: Current Perspectives on the Disease Status. Adv Exp Med Biol. 2019; 1152:51-64. DOI: 10.1007/978-3-030-20301-6_4. View

20.

Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X . Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35(3):428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. View